Novo Nordisk

We’re expanding our US manufacturing capacity.   This year, we plan to invest 4.1 billion US dollars (approx 27 billion Danish kroner) to build a second fill and finishing manufacturing facility in Clayton, North Carolina.   With this investment, we will create 1000 new jobs and grow our ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases.   Learn more about the news here 👉 https://lnkd.in/gu4MH2U   #NovoNordisk #DrivingChange #Manufacturing #Production 

Curious to hear the latest scientific conversations by leading experts? 🔬 Access videos, articles, and more at Novo Nordisk CongressHub: https://lnkd.in/dbvSK_tC #NovoNordisk #DrivingChange #Innovation

Genetics is one of many factors that play a role in a person’s likelihood of developing obesity. Did you know that the heritability of obesity is as high as 40-70%? Learn more about the multiple factors impacting people living with obesity: https://lnkd.in/eCyWpsQ #NovoNordisk #DrivingChange #Obesity 

We’re on a mission to drive change for millions of people living with chronic diseases and we need talents to help shape the future.   Did you know that we currently have around 1,000 open positions across the world? Check out our career site to see if there is a match for you: https://lnkd.in/dfHdaYP #NovoNordisk #DrivingChange #Career

It takes more than medicine to defeat chronic diseases.   It takes sport, song, culture, collaboration, listening and partnership. Just ask these inspiring people who are making big changes to the health of their communities - each in their own unique way. #NovoNordisk #DrivingChange #Health

Missed anything from #ISTH2024? Catch up on the exciting updates from the International Society on #Thrombosis and #Haemostatis at Novo Nordisk CongressHub 👉 https://bit.ly/45rxuxI

28 June marks the anniversary of the pivotal Stonewall uprising in 1969, which ignited the modern LGBTQ+ rights movement.   We have partnered with Stonewall to focus on everyday inclusion for our LGBTQ+ colleagues, fostering an environment where everyone can thrive. To kick off the partnership, we are joining their Rainbow Laces campaign, which aims to spark dialogue around how we can all become active allies for LGBTQ+ inclusion, both in the workplace and in making sport everyone's game.    The ask is simple – lace up to speak up!   Learn more abut our partnership here: https://lnkd.in/dfT5m4AS

The only way we can overcome low awareness of #sicklecelldisease and the stigmas faced by people living with it is by starting more conversations. This #WorldSickleCellDay we’re asking you to join us in raising awareness. Have one conversation with one other person about Sickle Cell Disease today. You can learn more about it here: https://lnkd.in/dM-YdTN We are committed to a future where it is possible to #liveunlimited with sickle cell disease, are you? #WorldSickleCellDay #WSCD2024

Exciting developments are underway at our production site in Chartres, France!   This week, members of our leadership team and board visited the site to see how we’re investing in and significantly expanding our facilities to meet the needs of millions of people living with diabetes, obesity, and other serious chronic diseases. By 2028, we aim to welcome 500 new colleagues, and increase our capacity to serve many more patients.   A special thanks to our 1700 dedicated colleagues at Chartres, who produce life-saving treatments.

Did you know? MASH, or metabolic dysfunction-associated steatohepatitis, is a serious, progressive, metabolic disease affecting the liver, which can be fatal if not managed properly. It is often described as a ‘silent disease’ due to the lack of specific symptoms in the early stages of the disease, which often contributes to a delay in diagnosis. 13 June is Global #FattyLiverDay 🌎 Learn more about living with the condition and the impact of a late diagnosis from Tania. Watch Tania’s story here: https://lnkd.in/dAw55qZV At Novo Nordisk, we are committed to continuing our research with the ambition of developing innovations that can help address the underlying cause of this disease. We hope to double diagnostic rates for people living with moderate to advanced MASH by 2027 💙